Provided by Tiger Trade Technology Pte. Ltd.

Spero Therapeutics Inc.

1.23
+0.01501.23%
Post-market: 1.250.0165+1.34%16:28 EDT
Volume:645.51K
Turnover:794.76K
Market Cap:71.63M
PE:9.63
High:1.26
Open:1.23
Low:1.20
Close:1.22
52wk High:3.08
52wk Low:1.08
Shares:58.23M
Float Shares:45.59M
Volume Ratio:1.44
T/O Rate:1.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1278
EPS(LYR):0.1500
ROE:19.17%
ROA:7.19%
PB:1.62
PE(LYR):8.20

Loading ...

Spero Therapeutics - Innovent to Receive Payments Totaling About $1.1 Bln Plus Tiered Royalties

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - Innovent to Initiate Phase 2 Trial for Sjögren’s Disease in China by Early 2027

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - to Initiate Phase 2 Trial for SP001 in Igg4-rd in Q2 2027

THOMSON REUTERS
·
Jul 14

Innovent Biologics - Spero Receives Exclusive Global Rights to Ibi355 Excluding Greater China

THOMSON REUTERS
·
Jul 14

Innovent Biologics and Spero Therapeutics Announce Exclusive License for Ibi355 (sp001), a Phase 2-ready Third-generation Anti-cd40l Antibody

THOMSON REUTERS
·
Jul 14

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors

GlobeNewswire
·
Jul 08

Spero Therapeutics Shareholders Approved Increase in Authorized Common Shares to 240 Million

Reuters
·
Jun 26

Spero Therapeutics says FDA approves Utebzi oral antibiotic for complicated UTIs in adults

Reuters
·
Jun 23

GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections

MT Newswires Live
·
Jun 18

GSK Says cUTI Oral Antibiotic Tebipenem Approved By US FDA

Reuters
·
Jun 17

GSK, Spero Therapeutics announce FDA approval of Utebzi

TIPRANKS
·
Jun 17

US FDA approves GSK's oral antibiotic for drug-resistant UTIs

Reuters
·
Jun 17

BRIEF-FDA Approves First Oral Carbapenem Therapy For Complicated Urinary Tract Infections

Reuters
·
Jun 17

GSK - Tebipenem Pivoxil Expected to Be Available in US by End of 2026

THOMSON REUTERS
·
Jun 17

Promising Penny Stocks To Consider In May 2026

Simply Wall St.
·
May 15

Spero Therapeutics Q1 revenue drops on decreased clinical activity

Reuters
·
May 14

Spero Therapeutics Q1 Operating Expenses USD 7.796 Million

Reuters
·
May 14

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

THOMSON REUTERS
·
May 14

Spero Therapeutics Q1 Net Income USD -7.203 Million

THOMSON REUTERS
·
May 14

Spero Therapeutics Q1 EPS USD -0.13

THOMSON REUTERS
·
May 14